FUSN Insider Trading Activity and SEC Form 4 Filings
FUSN insider trading summary
No open-market insider purchases or sales of Fusion Pharmaceuticals Inc. (FUSN) have been reported on SEC Form 4 in the past 12 months.
Latest FUSN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 11, 2022 | Steven Gannon | Director | Buy | $90K (44,400 @ $2.03) |
| Apr 27, 2022 | John Valliant | Chief Executive Officer | Sell | $27K (4,511 @ $6.03) |
| Apr 26, 2022 | John Valliant | Chief Executive Officer | Sell | $13K (2,147 @ $6.07) |
| Apr 25, 2022 | John Valliant | Chief Executive Officer | Sell | $12K (2,036 @ $6.03) |
| Apr 21, 2022 | John Valliant | Chief Executive Officer | Sell | $6K (922 @ $6.01) |
| Apr 20, 2022 | John Valliant | Chief Executive Officer | Sell | $2K (367 @ $6.02) |
| Apr 13, 2022 | John Valliant | Chief Executive Officer | Sell | $77K (11,994 @ $6.41) |
| Apr 12, 2022 | John Valliant | Chief Executive Officer | Sell | $130K (18,255 @ $7.10) |
| Apr 11, 2022 | John Valliant | Chief Executive Officer | Sell | $19K (2,600 @ $7.37) |
| Apr 8, 2022 | John Valliant | Chief Executive Officer | Sell | $6K (826 @ $7.52) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.